Naropin

Phase 1Small molecule

TTaiwan Liposome Company

Naropin is one of 39 small molecule programs targeting Inguinal hernia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inguinal HerniaActive, not recruiting

Inguinal HerniaPhase 1

Active, not recruiting

Competition

Competitive Landscape

66 competitors in Inguinal Hernia

#DrugCompanyPhaseTrials

Naropin

FFresenius Kabi Oncology Ltd.

Approved

3 2

Marcaine

IInnocoll

Approved

3 3

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

2 4

Ancef

BBaxter Healthcare Corporation

Approved

1 5

Advil

KKenvue Brands

Approved

1 6

Oxycontin

PProtega

Approved

1 7

Garamycin

SSchering-Plough

Approved

1 8

Cymbalta

Alnylam Pharmaceuticals

Phase 3

1 9

Marcaine

UUniversity of Chicago

Approved

2 10

Opioids

SSahlgrenska University Hospital

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Postsurgical Pain Management2 trials

Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management

Completed·TTaiwan Liposome Company·Phase 1/2·NCT03591146·65 enrolled

A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

Completed·TTaiwan Liposome Company·Phase 2·NCT03838133·150 enrolled

Knee Replacement Surgery1 trial

Analgesia After Total Knee Replacement Surgery

Completed·SSt. Antonius Hospital·N/A·NCT01489631·81 enrolled

Local Infiltration1 trial

Dose-Escalation, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GB-6002 Local Infiltration in Healthy Male Adults

Completed·GG2GBio, Inc.·Phase 1·NCT06095973·40 enrolled

Lumbar Spine Surgery1 trial

Peri-Incisional Drug Injection in Lumbar Spine Surgery

Withdrawn·UUniversity of Minnesota·Phase 3·NCT03513445

Inguinal hernia1 trial

A Trial of HR18034 in Inguinal Hernia Repair

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04551924·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Naropin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Naropin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Naropin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taiwan Liposome Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TTaiwan Liposome Company

Naropin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Postsurgical Pain Management2 trials

Knee Replacement Surgery1 trial

Local Infiltration1 trial

Lumbar Spine Surgery1 trial

Inguinal hernia1 trial

References

Drug Info

Quick Facts

Related News